Rieckermann designs Vietnam’s first mRNA COVID-19 vaccine production facility
With the support of the Vietnamese government and the ministry of health, Vingroup, the largest conglomerate in Vietnam and one of the biggest in Asia, is establishing a manufacturing facility in the capital Hanoi for the production of mRNA COVID-19 vaccines. The product is developed by Arcturus Therapeutics Holdings Inc., USA, with whom Vingroup signed an exclusive contract for the transfer of technology. With a planned capacity of up to 200 million doses per year, VinBioCare Biotechnology JSC, Vingroup’s newly established pharmaceutical company, has set up a fast-track project to contribute to Vietnam’s fight against COVID-19.
VinBioCare’s vaccine facility of just under 9,000 sqm is located inside VinSmart’s electronic equipment complex in Hoa Lac Hi-tech Park (Thach That District, Hanoi), and has a total investment estimated at USD200 million.
We are pleased to announce that VinBioCare has selected Rieckermann as their preferred consultant to deliver design, project management, and GMP management services for this ambitious project. Our services include concept design, basic design, detail design review, project management, construction supervision, commissioning, qualification, technology transfer, and US FDA certification support.
With this progressive Vingroup project, Rieckermann has once again demonstrated the undeniable value it offers to customers looking to accelerate their time to market. With established in-house pharmaceutical solutions that comprise Machinery, Engineering, and Technical Services, as well as comprehensive GMP consulting that facilitates product registration in European and US markets, Rieckermann is fast becoming the first choice industrial solution provider for pharmaceutical customers across our target markets.